Loading clinical trials...
Loading clinical trials...
Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Undergoing Dose-Adjusted Treatment With A Maximally Intensive Busulfex-Based Therapeutic Regimen
Conditions
Interventions
rabbit anti-thymocyte globulin (ATG)
therapeutic allogeneic lymphocytes
+6 more
Locations
1
United States
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, United States
Start Date
October 1, 2005
Primary Completion Date
November 1, 2015
Completion Date
November 1, 2015
Last Updated
July 17, 2017
NCT07249528
NCT04570423
NCT06735690
NCT05564390
NCT00131014
NCT03050268
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions